<DOC>
	<DOCNO>NCT01478477</DOCNO>
	<brief_summary>This randomize pilot trial study omega-3 fatty acid prevent joint symptom patient stage I-III breast cancer receive anastrozole , exemestane , letrozole . Omega-3 fatty acid supplement may lessen prevent joint stiffness pain patient receive hormone therapy breast cancer .</brief_summary>
	<brief_title>Omega-3 Fatty Acids Preventing Joint Symptoms Patients With Stage I-III Breast Cancer Receiving Anastrozole , Exemestane , Letrozole</brief_title>
	<detailed_description>OBJECTIVES : I . To assess feasibility evaluate joint symptom postmenopausal woman breast cancer randomize n-3 PUFA ( omega-3 fatty acid ) vs. placebo supplementation use Functional Assessment Cancer Therapy-Breast ( FACT-B ) endocrine subscale ( FACT-ES ) , Brief Pain Inventory ( BPI ) Stanford 's Health Assessment -Disability Index ( HAS ) first 6 month adjuvant aromatase inhibitor ( AI ) therapy . II . To preliminarily evaluate efficacy n-3 PUFA vs. placebo supplementation AI induce joint symptom . III . To explore blood image base biomarkers ( plasma red blood cell [ RBC ] level n-3 PUFAs , inflammatory cytokine receptor , intra-articular tenosynovial inflammation musculoskeletal magnetic resonance image [ MRI ] image ) AI-induced joint symptom woman AI therapy randomize n-3 PUFAs vs. placebo supplementation . OUTLINE : Patients randomize 1 2 treatment arm . ARM I : Patients receive omega-3 fatty acid orally ( PO ) daily ( QD ) 6 month absence disease progression unacceptable toxicity . ARM II : Patients receive placebo PO QD 6 month absence disease progression unacceptable toxicity .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>Women diagnose breast cancer stag IIII initiate first adjuvant AI therapy Food Drug Administration ( FDA ) approve AIs ( anastrozole , exemestane , letrozole ) Concurrent gonadotropinreleasing hormone ( GnRH ) agonist therapy allow Concurrent breast related radiation therapy allow Prior tamoxifen use allow Prior chemotherapy allow History osteoarthritis and/or fibromyalgia allow Ability understand willingness sign write informed consent document Metastatic malignancy kind Rheumatoid arthritis type autoimmune inflammatory joint disease , exception osteoarthritis fibromyalgia AI use &gt; 2 week prior study enrollment Known bleeding disorder History diabetes mellitus , heart disease TIA/stroke Current use warfarin anticoagulant Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement Daily use n3 PUFA concentrate capsule regular supplement might interact n3 PUFA supplement within six month study initiation ; sporadic use n3 PUFA supplement may eligible 3month washout period prior randomization Pregnant nursing woman Known sensitivity allergy fish fish oil Concurrent use daily full dose aspirin ( â‰¥ 325 mg/day ) , nonsteroidal antiinflammatory drug ( NSAIDs ) NSAIDcontaining product steroid ; one month washout period require prior randomization Unable give inform consent In patient consent optional MRIs , contraindication MRI examination include limited ferromagnetic metal body , pacemaker , severe claustrophobia</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Breast Cancer</keyword>
</DOC>